tetano
Editor, Senior Moderator
Thromb Haemost
. 2023 May 12.
doi: 10.1055/s-0043-1768921. Online ahead of print. Hemostatic Profile and Serological Response of Patients with Immune Thrombotic Thrombocytopenic Purpura after Receiving BNT162b2 Vaccine: A Prospective Study
Francesca Schieppati[SUP] 1 [/SUP], Laura Russo[SUP] 1 [/SUP], Sara Gamba[SUP] 1 [/SUP], Elisa Galimberti[SUP] 2 [/SUP], Cinzia Giaccherini[SUP] 1 [/SUP], Carmen J Tartari[SUP] 1 [/SUP], Silvia Bolognini[SUP] 1 [/SUP], Cristina Verzeroli[SUP] 1 [/SUP], Chiara Ticozzi[SUP] 1 [/SUP], Luca Barcella[SUP] 1 [/SUP], Marina Marchetti[SUP] 1 [/SUP], Anna Falanga[SUP] 1 2 [/SUP]
Affiliations
Introduction: Coronavirus disease is a clinical challenge for patients with autoimmune conditions. Patients affected by immune thrombotic thrombocytopenic purpura (iTTP) are particularly vulnerable to SARS-CoV-2 infection. Protecting these patients with vaccination is therefore mandatory, although concerns may exist on a possible increased thrombotic risk or risk of disease relapse after vaccine exposure. So far, there is no information on serological response and hemostatic activation in iTTP patients after SARS-CoV-2 vaccination.
Materials and methods: In this study, in April 2021, we enrolled iTTP patients in clinical remission and on regular outpatient follow-up to receive the first and second dose BNT162b2 vaccine as a part of a prospective trial aimed at monitoring for 6 months after vaccination the occurrence of subclinical laboratory signs of clotting activation, as well as overt thrombotic complications or disease relapse. The seroconversion response was monitored in parallel. The results were compared with those of control non-iTTP subjects.
Results: A moderate decrease of ADAMTS-13 activity was recorded at 3 and 6 months in five patients with normal values at baseline, while an ADAMTS-13 relapse occurred at 6 months in one patient. Abnormalities in the endothelium activation biomarkers postvaccination were observed in iTTP patients compared with controls. The immunological response to vaccine was overall positive. No clinical iTTP relapses or thrombotic events manifested in the 6 month-follow-up after vaccination.
Conclusion: The results of this study are in favor of efficacy and safety of mRNA vaccines in patients with iTTP, and highlight the importance of long-term monitoring of iTTP patients.
. 2023 May 12.
doi: 10.1055/s-0043-1768921. Online ahead of print. Hemostatic Profile and Serological Response of Patients with Immune Thrombotic Thrombocytopenic Purpura after Receiving BNT162b2 Vaccine: A Prospective Study
Francesca Schieppati[SUP] 1 [/SUP], Laura Russo[SUP] 1 [/SUP], Sara Gamba[SUP] 1 [/SUP], Elisa Galimberti[SUP] 2 [/SUP], Cinzia Giaccherini[SUP] 1 [/SUP], Carmen J Tartari[SUP] 1 [/SUP], Silvia Bolognini[SUP] 1 [/SUP], Cristina Verzeroli[SUP] 1 [/SUP], Chiara Ticozzi[SUP] 1 [/SUP], Luca Barcella[SUP] 1 [/SUP], Marina Marchetti[SUP] 1 [/SUP], Anna Falanga[SUP] 1 2 [/SUP]
Affiliations
- PMID: 37172940
- DOI: 10.1055/s-0043-1768921
Introduction: Coronavirus disease is a clinical challenge for patients with autoimmune conditions. Patients affected by immune thrombotic thrombocytopenic purpura (iTTP) are particularly vulnerable to SARS-CoV-2 infection. Protecting these patients with vaccination is therefore mandatory, although concerns may exist on a possible increased thrombotic risk or risk of disease relapse after vaccine exposure. So far, there is no information on serological response and hemostatic activation in iTTP patients after SARS-CoV-2 vaccination.
Materials and methods: In this study, in April 2021, we enrolled iTTP patients in clinical remission and on regular outpatient follow-up to receive the first and second dose BNT162b2 vaccine as a part of a prospective trial aimed at monitoring for 6 months after vaccination the occurrence of subclinical laboratory signs of clotting activation, as well as overt thrombotic complications or disease relapse. The seroconversion response was monitored in parallel. The results were compared with those of control non-iTTP subjects.
Results: A moderate decrease of ADAMTS-13 activity was recorded at 3 and 6 months in five patients with normal values at baseline, while an ADAMTS-13 relapse occurred at 6 months in one patient. Abnormalities in the endothelium activation biomarkers postvaccination were observed in iTTP patients compared with controls. The immunological response to vaccine was overall positive. No clinical iTTP relapses or thrombotic events manifested in the 6 month-follow-up after vaccination.
Conclusion: The results of this study are in favor of efficacy and safety of mRNA vaccines in patients with iTTP, and highlight the importance of long-term monitoring of iTTP patients.